Research graph
References from Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis. Local targets link to admitted publications; unresolved targets remain external evidence.
Pleiotropic effects of statins on the cardiovascular system
10.1161/circresaha.116.308537 · 2017 · External reference
Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC
10.1097/hep.0000000000000278 · 2023 · External reference
Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population- based study
10.1002/hep.29172 · 2017 · External reference
Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study
10.1111/apt.14243 · 2017 · External reference
Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis c-related compensated cirrhosis
10.1053/j.gastro.2015.10.007 · 2016 · External reference
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial
10.1053/j.gastro.2009.01.043 · 2009 · External reference
Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial
10.1016/j.dld.2015.07.156 · 2015 · External reference
Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension
10.1097/meg.0000000000001006 · 2018 · External reference
Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis
10.1053/j.gastro.2016.01.004 · 2016 · External reference
Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells
10.1016/j.jhep.2010.04.025 · 2010 · External reference
Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats
10.3389/fphys.2013.00195 · 2013 · External reference
KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins
10.1136/gutjnl-2014-308338 · 2015 · External reference
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase
10.1002/hep.21673 · 2007 · External reference
Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension
10.1136/gutjnl-2014-308800 · 2015 · External reference
Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats
10.1016/j.jhep.2007.01.020 · 2007 · External reference
Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population- based study
10.1002/hep.29172 · 2017 · External reference
Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C
10.1016/j.jhep.2014.08.013 · 2015 · External reference
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES
10.1002/hep.28506 · 2016 · External reference
Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection
10.1016/j.jhep.2015.07.006 · 2015 · External reference
Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study
10.1038/ajg.2016.179 · 2016 · External reference
Statins are associated with a decreased risk of severe liver disease in invididuals with noncirrhotic chronic liver disease
10.1016/j.cgh.2023.04.017 · 2024 · External reference
Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study
10.1002/hep4.2022 · 2022 · External reference
Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis
10.1016/j.cgh.2017.04.039 · 2017 · External reference
Statins exposure and adverse events in participants with chronic viral hepatitis: a meta-analysis based on cohort studies
10.1038/s44355-025-00020-4 · 2025 · External reference
Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality
10.1001/jamanetworkopen.2023.20222 · 2023 · External reference
Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review
10.1016/j.atherosclerosis.2006.11.036 · 2007 · External reference
Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis
10.1136/gut.51.2.265 · 2002 · External reference
Metabolic syndrome associated with primary biliary cirrhosis
10.1097/mcg.0000000000000029 · 2015 · External reference
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
10.1016/j.jhep.2017.03.022 · 2017 · External reference
Treatment of dyslipidemia in common liver diseases
10.1016/j.cgh.2018.04.023 · 2018 · External reference
Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis
10.1111/liv.12191 · 2013 · External reference
Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study
10.1097/hep.0000000000001701 · 2026 · External reference
Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases
10.1002/hep.32117 · 2022 · External reference
Molecular diagnostics of primary biliary cirrhosis
10.1517/17530059.2.6.621 · 2008 · External reference
Molecular diagnostic testing for primary biliary cholangitis
10.1080/14737159.2016.1217159 · 2016 · External reference
Variant and specific forms of autoimmune cholestatic liver diseases
10.1007/s00005-019-00550-9 · 2019 · External reference
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
10.1007/bf00432479 · 1978 · External reference
Global & ERN Rare-Liver PBC Study Groups. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
10.1016/j.jhep.2022.06.017 · 2022 · External reference
Hellenic Autoimmune Liver Diseases Study Group. Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis
2026 · External reference
Early primary biliary cirrhosis:biochemical response to treatment and prediction of long-term outcome
10.1016/j.jhep.2011.02.031 · 2011 · External reference
Global PBC Study Group. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy
10.1053/j.gastro.2015.07.061 · 2015 · External reference
Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece
10.1016/j.ejim.2017.05.006 · 2017 · External reference
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.jhep.2024.04.031 · 2024 · External reference
Prediction of 10-year cardiovascular disease risk by diabetes status and lipoprotein-a levels; the HellenicSCORE II
10.1016/j.hjc.2023.10.001 · 2024 · External reference
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 · External reference
Statins in primary biliary cholangitis: Untangling promise from bias
10.1097/hep.0000000000001722 · 2026 · External reference
Association between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure
2023 · External reference
Statin use and risks of hepatocellular carcinoma and liver fibrosis in chronic liver disease
10.1001/jamainternmed.2025.0115 · 2025 · External reference
Current trends and characteristics of hepatocellular carcinoma in patients with autoimmune liver diseases
10.3390/cancers13051023 · 2021 · External reference
